Blue Jay Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Blue Jay Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$6.74M	Buy	+120,000	New	+$4.81M	4.59%	13

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Blue Jay Capital Management's PTLA Position: Q2 2017 in Review

Blue Jay Capital Management opened a new position in Portola Pharmaceuticals, Inc. (PTLA) in Q2 2017: 120,000 shares worth $6.74M. The stake represents 4.59% of the portfolio and ranks #13 among its holdings.

206 funds tracked by Wall St. Rank hold PTLA as of Q2 2017.

Blue Jay Capital Management held 120,000 shares of Portola Pharmaceuticals, Inc. worth $6.74M as of Q2 2017.
Portola Pharmaceuticals, Inc. was a new Blue Jay Capital Management position in Q2 2017.
Portola Pharmaceuticals, Inc. made up 4.59% of Blue Jay Capital Management's portfolio in Q2 2017, its #13 holding.
206 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2017.

Based on Blue Jay Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.